NFE2L2 and neoplasm: Interestingly, by using these cells, the authors demonstrated that subtoxic doses of the multikinase inhibitor Sorafenib, normally used to target tumor angiogenesis, were able to reverse the drug resistance suppressing the NRF2 increase induced by 5-FU, although the mechanisms were not fully elucidated.